1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6BF021B77BD9E1786852577EC002957C4
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/onglyza-case-study-avoid-new-product-launch-problems?opendocument
18
19opendocument
203.88.156.58
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Sales and Marketing New Product Development and Launch Planning and Coordinating Launch Communication Activities

Onglyza Case Study: Lack of Differentiation Mutes a Launch

ID: 5109


Features:

31 Info Graphics

16 Narratives


Pages/Slides: 43


Published: Pre-2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Onglyza Case Study: Lack of Differentiation Mutes a Launch"

STUDY OVERVIEW

Onglyza, a DPP-4 inhibitor class of anti-diabetes drug, was the second DPP-4 to the market behind the blockbuster Januvia. Its development partners, Bristol-Myers Squibb and AstraZeneca, expected the oral therapy to win enough share from Januvia to become a blockbuster itself. However, the similarities between the two DPP-4 inhibitors were so striking on critical factors - safety, efficacy, convenience and price - that there was no clear differentiation for prescribers, patients and payers. Marketing missteps exacerbated the situation and the end result for Onglyza was a muted launch for a promising product.

Best Practices, LLC created this case study to illustrate the challenges of differentiating similar products in a competitive marketplace and to highlight the critical nature of positioning in a new product launch. Launch leaders can use this study to better understand and avoid the launch pitfalls that can mar the market entry of products facing a crowded market.


KEY TOPICS

  • Insights from Onglyza’s Launch
  • Initial Product Profile Promised a Clear Path to Market
  • A Launch and Slow Uptake
  • Onglyza Lacked a Clear Differentiation Message
  • Onglyza Didn’t Win Over Payers
  • Onglyza Tripped up by Marketing Missteps


SAMPLE KEY FINDING
  • Safety: Be aware of differences in safety and side effects between therapies and look for any area that can be highlighted in physician and patient education. Consider dosing, sub-populations, meta-analyses, and primary/secondary benefits.
  • Reach out to KOLs Early to Find Champions: In a crowded marketplace, it is critical to have KOLs who believe in your product and who will stand up and recommend it to colleagues.


METHODOLOGY

Insights were drawn from extensive secondary research and interviews with launch leaders in both marketing and strategy at a Top 10 pharma company.


Industries Profiled:
Pharmaceutical


Companies Profiled:
Bristol-Myers Squibb; AstraZeneca


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.